NeoGenomics Executive and Leadership Team

Anthony Zook, the Chief Executive Officer at NeoGenomics, directs the company's overarching strategy and operational execution. Zook guides the organization's mission to provide advanced cancer-focused genetic testing services, ensuring alignment with market demands and scientific advancements. This leadership involves overseeing the network of laboratories that serve hospitals, pathologists, oncologists, and researchers across the United States. By focusing on innovation and service excellence, Anthony Zook drives the expansion of NeoGenomics' capabilities in cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, and molecular testing. The Chief Executive Officer's role is critical in fostering collaborations and maintaining the company's position as a leader in diagnostic solutions, ultimately impacting the development of targeted therapies and improved patient care.

Douglas Oort, the Executive Chairman & Chief Executive Officer at NeoGenomics, provides strategic oversight and executive leadership for the company's long-term vision. Oort's responsibilities encompass guiding the board of directors and ensuring the effective implementation of corporate strategies across all business units. This dual role involves setting the direction for NeoGenomics' extensive network of cancer-focused genetic testing laboratories, which deliver vital services to healthcare providers and researchers nationwide. Douglas Oort's leadership is instrumental in navigating the complex landscape of genetic and molecular diagnostics, driving growth, and reinforcing the company's commitment to advancing cancer care. The Executive Chairman & Chief Executive Officer's focus remains on enhancing operational efficiency and expanding the company's market reach.

George Cardoza, the Chief Financial Officer at NeoGenomics, directs all financial operations and strategic financial planning for the organization. Cardoza manages the company's fiscal health, overseeing budgeting, forecasting, and financial reporting to ensure robust economic performance. This leadership role is crucial for supporting NeoGenomics' extensive network of cancer-focused genetic testing laboratories, which provide essential diagnostic services across the United States. The Chief Financial Officer's responsibilities include capital allocation, investor relations, and driving financial strategies that enable the company's growth and innovation in areas like cytogenetics, molecular testing, and pathology consultation services. By maintaining financial discipline, George Cardoza ensures the company can continue its mission of advancing cancer care through cutting-edge diagnostic solutions.

Warren Stone, the President & Chief Operating Officer at NeoGenomics, directs the day-to-day operational activities and oversees the execution of strategic initiatives across the company's laboratory network. Stone's leadership ensures the efficient and effective delivery of NeoGenomics' comprehensive cancer-focused genetic and molecular testing services to clients throughout the United States. This role involves managing laboratory operations, supply chain logistics, and quality control to maintain the highest standards of diagnostic accuracy and service reliability. Warren Stone's responsibilities extend to optimizing operational workflows, driving process improvements, and fostering a culture of excellence within the organization. The President & Chief Operating Officer's focus is on enhancing operational capacity and ensuring seamless service delivery to support clinicians and researchers in advancing cancer care.

Michelle Backus, the Vice President, Enterprise Platforms and Interim Chief Technology Officer at NeoGenomics, spearheads the development and management of the company's core technology infrastructure and enterprise platforms. Backus oversees the technological strategies that support NeoGenomics' comprehensive genetic and molecular testing services, ensuring scalability, security, and efficiency across its laboratory network. This critical role involves guiding the integration of advanced digital solutions and data management systems essential for processing complex genomic data. Michelle Backus's leadership ensures that the technology backbone effectively supports the company's mission to provide advanced diagnostic insights to hospitals, pathologists, oncologists, and researchers. The Interim Chief Technology Officer's focus is on optimizing platform performance and driving technological innovation to enhance service delivery and support future growth initiatives.

Derek Lyle, the Chief Medical Officer at NeoGenomics, provides critical medical and scientific leadership, guiding the company's diagnostic development and clinical strategy. Lyle oversees the interpretation of complex genetic and molecular test results, ensuring the highest standards of clinical validity and utility for patients and healthcare providers. This role is essential for NeoGenomics' mission to deliver advanced cancer-focused testing services, supporting oncologists, pathologists, and researchers in making informed treatment decisions. The Chief Medical Officer's expertise is vital in translating scientific advancements into actionable clinical insights and ensuring that NeoGenomics' service offerings remain at the forefront of precision medicine. Derek Lyle's leadership ensures the scientific integrity and clinical relevance of the company's diagnostic portfolio.